Entera Bio (ENTX) Net Cash Flow (2021 - 2026)
Entera Bio's (ENTX) quarterly Net Cash Flow came in at -$3.0 million in Q1 2026, down 124.82% YoY from $11.9 million in Q1 2025, and down 75.56% on a QoQ basis from -$1.7 million in Q4 2025.
Entera Bio (ENTX) Net Cash Flow (2021 - 2026) Analysis & Trends
Entera Bio (ENTX) has 6 years of Net Cash Flow data on file, last reported at -$3.0 million in Q1 2026.
- Quarterly Net Cash Flow fell 124.82% year-over-year to -$3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.7 million (down 175.81% YoY) and the FY2025 annual result came in at $6.2 million, up 365.8% from the prior year.
- Net Cash Flow retreated to -$3.0 million in Q1 2026, from -$1.7 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $11.9 million in Q1 2025 to a low of -$4.8 million in Q1 2022.
- A 5-year average of -$761823.5 and a median of -$1.7 million in 2025 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 750.93% in 2025, down 1337.82% in 2025.
- Tracing ENTX's Net Cash Flow over 5 years: stood at -$2.0 million in 2022, then soared by 269.27% to $3.4 million in 2023, then tumbled by 48.75% to $1.7 million in 2024, then plunged by 196.51% to -$1.7 million in 2025, then tumbled by 75.56% to -$3.0 million in 2026.
- The last three Net Cash Flow figures came in at -$3.0 million (Q1 2026), -$1.7 million (Q4 2025), and -$2.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Entera Bio | 161.44 Mn | 150.13 Mn | - | 6.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.49 Mn |
| Jun 30, 2026 | 6.49 Mn |
| Mar 31, 2026 | -2.96 Mn |
| Mar 31, 2026 | -2.96 Mn |
| Dec 31, 2025 | -1.69 Mn |
| Dec 31, 2025 | -1.69 Mn |
| Sep 30, 2025 | -2.30 Mn |
| Sep 30, 2025 | -2.30 Mn |
| Jun 30, 2025 | -1.71 Mn |
| Jun 30, 2025 | -1.71 Mn |
| Mar 31, 2025 | 11.93 Mn |
| Mar 31, 2025 | 11.93 Mn |
| Dec 31, 2024 | 1.75 Mn |
| Dec 31, 2024 | 1.75 Mn |
| Sep 30, 2024 | -2.14 Mn |
| Sep 30, 2024 | -2.14 Mn |
| Jun 30, 2024 | -119,000.00 |
| Jun 30, 2024 | -119,000.00 |
| Mar 31, 2024 | -1.83 Mn |
| Mar 31, 2024 | -1.83 Mn |